retatrutide safety clinical trial retatrutide FDA Approval Status 2026: Everything We Know So Far Retatrutide vs Mounjaro: A Doctor's

Does Pendulum Glucose Control need to be refrigerated

Independent, licensed providers on the Eden platform can help determine if a GLP-1 injection is appropriate based on a full medical evaluation

Nausea is the most common gastrointestinal side effect, affecting 44% of patients

Body comp matters more than scale weight for real Stephanie L., 33, Kelowna BC Resistance Training Lifting weights 2-3x weekly during treatment preserves muscle that would otherwise be lost during rapid weight reduction

As reported by the American Journal of Managed Care, the approval of an oral semaglutide formulation marked the beginning of what many are calling the oral GLP-1 era. In December 2025, the FDA approved the Wegovy (semaglutide) tablet as the first once-daily oral GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight

Retatrutide reduced HbA1c (a three-month average of blood sugar) by 1.8% at the 12mg dose in participants with type 2 diabetes